top of page

NAD+ and Peptide Therapy for Brain and Mental Wellness: What the Science Actually Supports

Writer: Merly Quias
Merly Quias
Oct 8
4 min read
Woman in a hospital recliner with IV, gazing upward as glowing golden light rises around her against a sunset city skyline.

NAD+ and Peptide Therapy for Brain and Mental Wellness:


An honest, evidence-first look at NAD+ and peptide therapies — what they are, what the research does and doesn’t show, and how to think about them as part of a mental-wellness plan.


NAD+ and peptide therapies have become some of the most talked-about tools in wellness — promoted for everything from sharper focus to more stable mood to “anti-aging.” Some of that excitement is grounded in real biology. Some of it runs ahead of the evidence. As a clinic built around evidence-based mental health care, we think you deserve the straight version: what’s genuinely supported, what’s still emerging, and what to watch out for.



What NAD+ actually is

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell in your body. It’s essential for turning food into usable energy, repairing DNA, and running the cellular “housekeeping” that keeps tissues — including brain tissue — healthy. NAD+ levels naturally decline with age and with certain stressors, which is the core reason it’s drawn interest as a target for supporting energy, resilience, and healthy aging.



What the research does support

Two things are reasonably well established in humans. First, NAD+ precursors — nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — reliably raise blood NAD+ levels. A 2022 randomized trial of NMN in healthy middle-aged adults found dose-dependent increases in NAD+ over 60 days, and a 2026 randomized trial in Nature Metabolism confirmed that both NR and NMN comparably raise circulating NAD+. Second, in these trials the precursors were generally safe and well tolerated at the doses studied.



What the research does NOT yet show

Here’s the honest part. Raising NAD+ levels is not the same as proving a specific health or mood benefit. When researchers look at real-world outcomes, the results are mixed. A 2025 systematic review and meta-analysis found that NMN and NR did not meaningfully improve muscle mass or physical function in older adults. And rigorous human trials specifically testing NAD+ for depression, anxiety, or cognition are limited and preliminary. In short: the biology is promising and the safety signal is encouraging, but the claim that NAD+ “treats” a mental health condition is not yet supported by strong clinical evidence.



NAD+ and mental wellness: a measured view

Because NAD+ is central to brain energy metabolism and cellular repair, there’s a plausible rationale for exploring it as a support for mental and cognitive wellness — particularly fatigue, brain fog, and the depleted feeling that often accompanies chronic stress or recovery. Many people report subjective benefits like improved energy and clarity. Those experiences are real and worth taking seriously, while also holding them alongside the current limits of the evidence. We think of NAD+ as a wellness adjunct to explore thoughtfully, not a stand-alone treatment for a diagnosed mental health condition.



Where peptides fit in

“Peptides” is a broad umbrella. Some — like the GLP-1 medications used for metabolic health — are FDA-approved and rigorously studied. Others marketed for recovery, cognition, or mood (for example, BPC-157, or nootropic peptides such as Semax and Selank) are investigational: human trial evidence is thin, and much of what circulates online comes from animal studies or unregulated sources. These may hold promise, but they should be approached with caution and clear-eyed expectations.



An important note on regulation

The regulatory landscape here is genuinely in flux, and it matters for your safety. As of 2025, the FDA has treated NMN as an investigational drug rather than a dietary supplement, and several popular peptides have moved on and off the FDA’s restricted compounding lists. This is exactly why sourcing and clinical oversight matter so much: quality, purity, dosing, and legality vary widely in this space. Working with a licensed clinician — rather than buying compounds online — is the single most important safeguard.



How we think about it at Refound Center

Our starting point is always evidence-based mental health care. Within that frame, we see NAD+ and select, appropriately-sourced therapies as potential complements for the right person — tools to support energy, recovery, and overall wellbeing, chosen individually and monitored over time. We won’t oversell them, and we’ll always be candid about what’s proven versus what’s promising. If something isn’t a good fit for your health or goals, we’ll tell you.



The bottom line

NAD+ is real, important cellular biology, and precursors can safely raise NAD+ levels — but the downstream benefits for mood and mental wellness are still being studied, and many peptide products remain investigational and loosely regulated. Approached honestly and under clinical supervision, these therapies may have a place in a broader wellness plan. Approached as a miracle cure or a DIY project, they’re a gamble. The difference is guidance.


Curious whether NAD+ or peptide therapy could complement your wellness plan? Refound Center offers clinician-guided consultations in the North Denver to Fort Collins area. Reach out and we’ll give you an honest, personalized assessment — no hype.




Medical disclaimer

This article is for general educational purposes only and is not medical advice, diagnosis, or treatment. NAD+ and peptide therapies are not a substitute for evidence-based mental health care. Regulatory status for some of these compounds is evolving; availability and appropriateness should be confirmed with a qualified clinician. If you are in crisis or thinking about harming yourself, call or text 988 (the Suicide & Crisis Lifeline) in the U.S.


Sources & further reading (studies identified via PubMed):

Yi L, et al. Efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, double-blind, placebo-controlled, dose-dependent clinical trial. GeroScience, 2022. https://doi.org/10.1007/s11357-022-00705-1

Christen S, et al. The differential impact of three different NAD+ boosters on circulatory NAD+ and microbial metabolism in humans. Nature Metabolism, 2026. https://doi.org/10.1038/s42255-025-01421-8

Prokopidis K, et al. The effect of nicotinamide mononucleotide and riboside on skeletal muscle mass and function: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle, 2025. https://doi.org/10.1002/jcsm.13799

U.S. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (compounded peptides guidance). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks


 
 
 

Comments


bottom of page